Rocket Pharmaceuticals (NASDAQ:RCKT) Given Buy Rating at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Rocket Pharmaceuticals (NASDAQ:RCKT) in a research note issued to investors on Friday,Benzinga reports. Chardan Capital currently has a $11.00 target price on the biotechnology company’s stock.

A number of other equities analysts have also weighed in on the stock. The Goldman Sachs Group upped their target price on shares of Rocket Pharmaceuticals to $3.00 and gave the stock a “sell” rating in a research report on Monday, March 2nd. TD Cowen upgraded shares of Rocket Pharmaceuticals to a “hold” rating in a report on Friday, December 19th. Wall Street Zen cut shares of Rocket Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, March 8th. Cantor Fitzgerald increased their price objective on shares of Rocket Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Friday, February 27th. Finally, Morgan Stanley set a $5.00 price objective on Rocket Pharmaceuticals in a research report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, Rocket Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $13.79.

Rocket Pharmaceuticals Stock Down 19.6%

NASDAQ RCKT opened at $3.77 on Friday. Rocket Pharmaceuticals has a 12 month low of $2.19 and a 12 month high of $8.26. The company has a current ratio of 6.38, a quick ratio of 6.38 and a debt-to-equity ratio of 0.07. The stock has a market cap of $411.38 million, a PE ratio of -1.88 and a beta of 0.39. The stock’s 50 day moving average is $4.03 and its 200 day moving average is $3.63.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.04. During the same quarter in the previous year, the business earned ($0.62) EPS. Research analysts predict that Rocket Pharmaceuticals will post -2.83 EPS for the current fiscal year.

Insider Buying and Selling at Rocket Pharmaceuticals

In related news, CEO Gaurav Shah sold 12,279 shares of the business’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $3.31, for a total value of $40,643.49. Following the sale, the chief executive officer owned 1,052,045 shares in the company, valued at approximately $3,482,268.95. The trade was a 1.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Martin Wilson sold 12,253 shares of the company’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,557.43. Following the sale, the general counsel directly owned 683,376 shares in the company, valued at approximately $2,261,974.56. The trade was a 1.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 29,415 shares of company stock worth $97,398 in the last 90 days. 24.76% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Monaco Asset Management SAM raised its position in Rocket Pharmaceuticals by 538.8% during the third quarter. Monaco Asset Management SAM now owns 2,892,261 shares of the biotechnology company’s stock valued at $9,429,000 after purchasing an additional 2,439,494 shares during the period. Maverick Capital Ltd. lifted its stake in shares of Rocket Pharmaceuticals by 60.9% in the 2nd quarter. Maverick Capital Ltd. now owns 8,363,813 shares of the biotechnology company’s stock valued at $20,491,000 after purchasing an additional 3,164,595 shares during the last quarter. Virtus Investment Advisers LLC boosted its holdings in shares of Rocket Pharmaceuticals by 134.6% in the 2nd quarter. Virtus Investment Advisers LLC now owns 30,630 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 17,572 shares during the period. Walleye Capital LLC increased its position in shares of Rocket Pharmaceuticals by 100.7% during the 2nd quarter. Walleye Capital LLC now owns 576,051 shares of the biotechnology company’s stock valued at $1,411,000 after purchasing an additional 288,963 shares during the last quarter. Finally, GSA Capital Partners LLP increased its position in shares of Rocket Pharmaceuticals by 502.3% during the 3rd quarter. GSA Capital Partners LLP now owns 224,276 shares of the biotechnology company’s stock valued at $731,000 after purchasing an additional 187,037 shares during the last quarter. Institutional investors own 98.39% of the company’s stock.

Key Headlines Impacting Rocket Pharmaceuticals

Here are the key news stories impacting Rocket Pharmaceuticals this week:

• Positive Sentiment: FDA approval of KRESLADI for severe pediatric LAD‑I — regulatory green light expands Rocket’s commercial path for a first‑in‑class gene therapy for a fatal childhood disorder; approval is narrowly targeted to patients without an HLA‑matched sibling donor, and the decision creates revenue potential and clinical/regulatory validation that could benefit the company’s pipeline. Proactive: Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI
• Positive Sentiment: Industry and media coverage emphasize milestone nature and platform validation — outlets note the approval could “clear the way” for future Rocket products, which supports longer‑term upside if the company executes commercially. BioSpace: Rocket’s Gene Therapy Wins FDA Greenlight
• Positive Sentiment: Analyst reaffirmation with a high price target — Chardan Capital reiterated a Buy and set an $11 target, signaling street conviction and implying substantial upside from current levels if commercialization prospects materialize. Benzinga: Chardan reaffirms Buy, $11 PT
• Neutral Sentiment: Unusually large options activity — a surge in call buying (noted the prior day) indicates speculative/short‑term trader interest around the approval news; this can amplify volatility but doesn’t directly change fundamentals. Seeking Alpha transcript and options note
• Negative Sentiment: Commercial and execution risks remain — small patient population for LAD‑I, reimbursement/pricing negotiations, manufacturing scale‑up, and post‑approval commitments (including potential confirmatory trials) could limit near‑term revenue and increase spending; these uncertainties explain why shares remain volatile and below some long‑term targets until commercial traction is shown. Reuters: Coverage of approval and market reaction

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.